Skip to main navigation Skip to search Skip to main content

Raloxifene, tamoxifen and vascular tone

  • Fung Ping Leung
  • , Suk Ying Tsang
  • , Chi Ming Wong
  • , Lai Ming Yung
  • , Yau Chi Chan
  • , Hok Sum Leung
  • , Xiaoqiang Yao
  • , Yu Huang

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

Abstract

1. Oestrogen deficiency causes progressive reduction in endothelial function. Despite the benefits of hormone-replacement therapy (HRT) evident in earlier epidemiological studies, recent randomized trials of HRT for the prevention of heart disease found no overall benefit. Instead, HRT users had higher incidences of stroke and heart attack. Most women discontinue HRT because of its many side-effects and/or the increased risk of breast and uterine cancer. This has contributed to the development of selective oestrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, as alternative oestrogenic agents. 2. A SERM is a molecule that binds with high affinity to oestrogen receptors but has tissue-specific effects distinct from oestrogen, acting as an oestrogen agonist in some tissues and as an antagonist in others. Clinical and animal studies suggest multiple cardiovascular effects of SERMs. For example, raloxifene lowers serum levels of cholesterol and homocysteine, attenuates oxidation of low-density lipoprotein, inhibits endothelial-leucocyte interaction, improves endothelial function and reduces vascular smooth muscle tone. 3. Available evidence suggests that raloxifene and tamoxifen are capable of acting directly on both endothelial cells and the underlying vascular smooth muscle cells and cause a multitude of favourable modifications of the vascular wall, which jointly contribute to improved local blood flow. The outcome of the Raloxifene Use for the Heart (RUTH) trial will determine whether raloxifene, currently approved for the treatment of post-menopausal osteoporosis, could substitute for HRT in alleviating cardiovascular symptoms in post-menopausal women. © 2007 The Authors.
Original languageEnglish
Pages (from-to)809-813
JournalClinical and Experimental Pharmacology and Physiology
Volume34
Issue number8
DOIs
Publication statusPublished - Aug 2007
Externally publishedYes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Endothelial function
  • Raloxifene
  • Sex hormone
  • Tamoxifen
  • Vascular tone

Fingerprint

Dive into the research topics of 'Raloxifene, tamoxifen and vascular tone'. Together they form a unique fingerprint.

Cite this